CD5 and cCLLa Expression in Chronic Lymphocytic Leukemia (CLL): Demonstration of Their Relative Prevalence and that of Other Common B-CLL Markers

References

• Preud'homme J. L., Seligman M. Surface bound immunoglobulins as a cell marker in human lymphoprolifera-tive diseases. Blood 1974; 3: 853
   Google Scholar
• Aisenberg A. C., Block K. L., Long J. C. Cell surface immunoglobulin in chronic lymphocytic leukemia and allied disorders. Am. J. Med. 1973; 55: 184
   PubMed Web of Science ®Google Scholar
• Catovsky D., Cherchi M., Okos A., Hedge U., Galton D. A. Mouse red blood cell rosettes in B lymphoproliferative disorders. Br. J. Haematol. 1976; 33: 173
   PubMed Web of Science ®Google Scholar
• Calgaris-Cappio F., Janossy G. Surface markers in chronic lymphoid leukemias of B cell type. Semin. Hematol. 1985; 22: 1
   PubMed Web of Science ®Google Scholar
• Wang C. J., Good R. A., Ammirati P., Dymbort G., Evans R. L. Identification of p69,71 complex expressed on human T cells sharing determinants with B type chronic lymphocytic cells. J. Exp. Med. 1980; 151: 1539
   PubMed Web of Science ®Google Scholar
• Royston I., Majda J. A., Baird Mersuve S. M., Griffiths J. C. Human T-cell antigens defined by monoclonal antibodies: The 65,000 dalton antigen to T-cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulins. J. Immunol. 1980; 125: 725–731
   PubMed Web of Science ®Google Scholar
• Agee J. F., Garver F. A., Faguet G. B. An antigen common to chronic lymphocytic and hairy cell leukemia cells not shared by normal lymphocytes nor by other leukemia cells. Blood 1986; 68: 62
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Monoclonal antibodies against the chronic lymphatic leukemia antigen, cCLLa: Characterization and reactivity. Blood 1987; 70: 437
   PubMed Web of Science ®Google Scholar
• Harris N. L., Bhan A. K. B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: Immunohistologic analysis and clinical correlation. Hum. Pathol 1985; 16: 829
   PubMed Web of Science ®Google Scholar
• Burns B. F., Warnke R. A., Doggett R. S., Rouse R. V. Expression of a T-cell antigen (Leu-1) by B-cell lymphomas. Am. J. Pathol. 1983; 113: 165
   PubMed Web of Science ®Google Scholar
• Medeiros L. J., Strieker J. G., Picker L. J., Gelb A. B., Weiss L. M., Warnke R. A. “Well-differentiated” lymphocytic neoplasms. Immunologic findings correlated with clinical presentation and morphologic features. Am. J. Pathol 1987; 129: 523
   PubMed Web of Science ®Google Scholar
• Calgaris-Cappio F., Gobbi M., Bofill M., Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J. Exp. Med. 1982; 155: 623
   PubMed Web of Science ®Google Scholar
• Hardy R. R., Hayakawa K. Development and physiology of Ly-1 B and its human homolog, Leu-1 B. Immunol. Rev. 1986; 93: 53
   PubMed Web of Science ®Google Scholar
• Casali P., Burastero S. E., Nakamura M., Inghirami G., Notkins A. L. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236: 77
   PubMed Web of Science ®Google Scholar
• Kipps T. J., Vaughan J. H. Genetic influence on the levels of circulating CD5 B lymphocytes. J. Immunol. 1987; 139: 1060
   PubMed Web of Science ®Google Scholar
• Hardy R. R., Hayakawa K., Shimizu M., Yamasaki K., Kishimoto T. Rheumatoid factor secretion from human leu-1+ B cells. Science 1987; 236: 81
   PubMed Web of Science ®Google Scholar
• Taniguchi O., Miyajima H., Hirano T., Noguchi M., Ueda A., Hashimoto H., Hirose S., Okumura K. The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis. J. Clin. Immunol. 1987; 7: 441
   PubMed Web of Science ®Google Scholar
• Dauphinee M., Tovar Z., Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum. 1988; 31: 642
   PubMed Web of Science ®Google Scholar
• Suzuki N., Sakane T., Engleman E. G. Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. J. Clin. Invest. 1990; 85: 238
   PubMed Web of Science ®Google Scholar
• Ault K. A., Antin J. H., Ginsgurg D., Orkin S. H., Rappeport J. M., Keohan M. L., Martin P., Smith B. R. Phenotype of recovering lymphoid cell populations after marrow transplantation. J. Exp. Med. 1985; 161: 1483
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Immunophenotypic diagnosis of clinical and preclinical chronic lymphatic leukemia by using monoclonal antibodies against the cCLLa, a CLL-associated antigen. Blood 1988; 72: 679
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Recommendations for Diagnosis, Staging and Response Criteria. Ann. Int. Med. 1989; 110: 236
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawatsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Marti G. E., Agee J. F. Clone emergence and evolution in chronic lymphocytic leukemia: Characterization and laboratory profiles of 25 patients. Leukemia & Lymphoma, (in press)
   Google Scholar
• Faguet G. B. Lymphocyte purification, an improved method: Qualitative and quantitative evaluation. Biomedicine 1974; 21: 153–157
   PubMedGoogle Scholar
• Kipps T. J. The CD5 B-cells. Adv. Immunol. 1989; 47: 117
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., Sobol R. E., Collins H. A., Beauregard J. C., Wormsley S. B., Royston I. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036
   PubMed Web of Science ®Google Scholar
• Neville D. M., Jr. Immunotoxins for in vivo therapy: where are we?. Ann. N. Y. Acad. Sci. 1987; 507: 155
   PubMed Web of Science ®Google Scholar
• Byers V. S., Baldwin R. W. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65: 329
   PubMed Web of Science ®Google Scholar
• Rostaing-Capaillon O., Casellas P. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxin in vivo. Cancer Res. 1990; 50: 2909–16
   PubMed Web of Science ®Google Scholar
• Laurent G., Pris J., Farcet J. P., Carayon P., Blythman H., Casellas P., Poncelet P., Jansen F. K. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients
   Google Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Response. Mod 1988; 7: 97
   PubMedGoogle Scholar
• Marti G. E., Faguet G. B., Benin P., Agee J. F., Washington G., Ruiz S., Vogt R., Noguchi P. Cytometry Suppl 1991; 12(5)488B, CD20 and CD5 expression in B-CLL.
   Google Scholar
• Agee J. F., Wang G., Faguet G. B. In vitro evaluation of a ricin A chain-based immunotoxin directed against the common chronic lymphocytic leukemia antigen (cCLLa): A potential biological agent for in vivo therapy. The FASEB J. 1990; 4: A1498
   Google Scholar
• Faguet G. B., Agee J. F. A deglycosylated ricin A chain-based immunotoxin directed against the common chronic lymphocytic leukemia antigen (cCLLa): in vitro specificity and cytotoxicity activit. Blood 1990; 76: 1063A
   Google Scholar
• Ragheb S., Lisak R. P. The frequency of CD5+ B-lymphocytes in the peripheral blood of patients with myasthenia gravis. Neurology 1990; 40: 1120
   PubMed Web of Science ®Google Scholar
• Mix E., Olsson T., Correale J., Baig S., Kostulas V., Olsson O., Link H. B-cells expressing CD5 are increased in cerebrospinal fluids of patients with multiple sclerosis. Clin. Exp. Immunol. 1990; 79: 21
   PubMed Web of Science ®Google Scholar
• Pater-Zyberk C., Maini R. N., Lam K., Kenedy T. D., Janossy G. A rheumatoid arthritis B cell subset express a phenotype similar to that of chronic lymphocytic leukemia. Arthritis Rheum. 1985; 28: 971
   PubMed Web of Science ®Google Scholar
• Borche L., Lim A., Binet J. L., Dighiero G. Evidence that CLL B-lymphocytes are frequently committed for the production of multispecific autoantibodies. Blood 1989; 74: 146A
   Google Scholar
• Dameshek W., Gunz F. Leukemia, 2nd Edition. Grune & Stratton, New York, NY 1964
   Google Scholar
• Marti G. E., Faguet G. B., Bertin P., Agee J. F., Washington G. C., Resto-Ruiz S., Carter P. H., Noguchi F. D. A. Cell cycle dependent expression of the common chronic lymphocytic leukemia antigen (cCLLa). Cytometry Suppl 1991; 12(5)489C
   Google Scholar